Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases

Vaccine

Volumn 26, Issue 18, 2008, Pages 2284-2296

  Bardotti, Angela ^a   Averani, Giovanni ^a   Berti, Francesco ^a   Berti, Stefania ^a   Carinci, Valeria ^a   D'Ascenzi, Sandro ^a   Fabbri, Barbara ^a   Giannini, Sara ^a   Giannozzi, Aldo ^a   Magagnoli, Claudia ^a   Proietti, Daniela ^a   Norelli, Francesco ^a   Rappuoli, Rino ^a   Ricci, Stefano ^a   Costantino, Paolo ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

Glycoconjugate vaccines; Neisseria meningitidis; Physicochemical characterisation

Indexed keywords

BACTERIAL POLYSACCHARIDE; BACTERIAL VACCINE; CARRIER PROTEIN; DIPHTHERIA TOXOID CRM197; GLYCOCONJUGATE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MENINGOCOCCUS VACCINE;

ARTICLE; BACTERIAL INFECTION; BACTERIAL MEMBRANE; COVALENT BOND; GLYCOSYLATION; IMMUNE RESPONSE; MENINGOCOCCOSIS; MOLECULAR WEIGHT; NEISSERIA MENINGITIDIS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REPRODUCIBILITY; SPECTROSCOPY;

CIRCULAR DICHROISM; MAGNETIC RESONANCE SPECTROSCOPY; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; VACCINES, CONJUGATE;

EID: 42249086105     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.01.022     Document Type: Article

References (30)

1. Pollard A.J. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J 23 12 (2004) S274-S279
2. Harrison L.H. Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev 19 1 (2006) 142-164
3. Jodar L., Feavers I.M., Salisbury D., and Granoff D.M. Development of vaccines against meningococcal disease. Lancet 359 (2002) 1499-1508
4. Stephens D.S. Conquering the meningococcus. FEMS Microbiol Rev 31 (2007) 3-14
5. Robbins J.B., Schneerson R., Szu S.C., and Pozsgay V. Bacterial polysaccharide-protein conjugate vaccines. Pure Appl Chem 71 5 (1999) 745-754
6. Finn A. Bacterial polysaccharide-protein conjugate vaccines. Brit Med Bull 70 (2004) 1-14
7. Jones C. Vaccines based on the cell surface carbohydrates of pathogenic bacteria. An Acad Bras Cienc 77 2 (2005) 293-324
8. Vliegenthart J.F.G. Carbohydrates based vaccines. FEBS Lett 580 (2006) 2945-2950
9. Ravenscroft N., and Jones C. Glycoconjugate vaccines. Curr Opin Drug Discov Dev 3 2 (2000) 222-231
10. Giannini G., Rappuoli R., and Ratti G. The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197. Nucleic Acids Res 12 10 (1984) 4063-4069
11. Jones C., and Lemercinier X. Use and validation of an NMR test for the identity and O-acetyl content of capsular polysaccharides from Neisseria meningitidis used in vaccine manufacture. J Pharm Biomed Anal 30 (2002) 1233-1247
12. 1H NMR assignment and detailed O-acetylation patterns of capsular polysaccharides from Neisseria meningitidis used in vaccine production. Carbohydr Res 296 (1996) 83-96
13. Jumel K., Ho M.M., and Bolgiano B. Evaluation of meningococcal C oligosaccaride conjugate vaccines by size-exclusion chromatography/multi-angle laser light scattering. Biotechnol Appl Biochem 36 (2002) 219-226
14. Crane D.T., Bolgiano B., and Jones C. Comparison of the diphtheria mutant toxin, CRM197, with a Haemophilus influenzae type-b polysaccharide-CRM197 conjugate by optical spectroscopy. Eur J Biochem 246 (1997) 320-327
15. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., et al. Measurement of protein using bicinchoninic acid. Anal Biochem 150 (1985) 76-85
16. Svennerholm L. Quantitative estimation of sialic acids. II. A coloriemtric resorcinol-hydrochloric acid method. Biochim Biophys Acta 24 3 (1957) 604-611
17. Ricci S., Bardotti A., D'Ascenzi S., and Ravenscroft N. Development of a new method for the quantitative analysis of the extra cellular polysaccharide of Neisseria meningitidis serogroup A by use of high-performance anion-exchange chromatography with pulsed-amperometric detection. Vaccine 19 (2001) 1989-1997
18. Bardotti A., Averani G., Berti F., Berti S., Galli C., Giannini S., et al. Size determination of bacterial capsular oligosaccharides used to prepare conjugate vaccines against Neisseria meningitidis groups Y and W135. Vaccine 23 (2005) 1887-1899
19. Costantino P., Viti S., Podda A., Velmonte M.A., Nencioni L., and Rappuoli R. Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine 10 10 (1992) 691-698
20. Costantino P., Norelli F., Giannozzi A., D'Ascenzi S., Bartoloni A., Viti S., et al. Size fractionation of bacterial capsular oligosaccharides for their use in conjugate vaccines. Vaccine 17 (1999) 1251-1263
21. Ravenscroft N., Averani G., Bartoloni A., Berti S., Bigio M., Carinci V., et al. Size determination of bacterial capsular oligosaccharides used to prepare conjugate vaccines. Vaccine 17 (1999) 2802-2816
22. Bennett M.J., and Eisenberg D. Refined structure of monomeric diphteria toxin at 2.3 A resolution. Protein Sci 3 (1994) 1464-1475
23. Lesinsky J.B., and Westerink M.A.J. Vaccines against polysaccharide antigens. Curr Drug Targets Infect Disord 1 (2001) 225-334
24. Anderson P.W., Pichichero M.E., Stein E.C., Porcelli S., Betts R.F., Connuck D.M., et al. Effect of oligosaccharide chain length, exposed terminal group, and hapten loading on the antibody response of human adults and infants to vaccines consisting of Haemophilus influenzae type b capsular antigen uniterminally coupled to the diphtheria protein CRM197. J Immunol 142 (1989) 2464-2468
25. Berry D.S., Lynn F., Lee C.H., Frasch C.E., and Bash M.C. Effect of O-acetylation of Neisseria meningitidis serogroup A capsular polysaccharide on development of functional immune responses. Infect Immun 70 7 (2002) 3707-3713
26. Richmond P., Borrow R., Findlow J., Martin S., Thornton C., Kartwright K., et al. Evaluation of de-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunological priming, and bactericidal activity against O-acetylated and de-O-acetylated serogroup C strains. Infect Immun 60 4 (2001) 2378-2382
27. Ho M.M., Lemercinier X., Bolgiano B., Crane D., and Corbel M.J. Solution stability studies of the subunit components of meningococcal C oligosaccharide-CRM197 conjugate vaccines. Biotechnol Appl Biochem 33 (2001) 91-98
28. Jackson L.A., Jacobson R.M., Reisinger K.S., Ganju J., Danzig L.E., and Dull P.M. Safety and immunogenicity of a tetravalent meningococcal ACWY glycoconjugate vaccine in healthy adolescents. Proceedings of the 44th Annual Meeting of IDSA. October 12-15, Toronto (2006)
29. Perrett K.P., Snape M.D., Ford K., Langley J.M., McNeil S., Ceddia F., et al. Immunogenicity and immune memory of a non-adjuvanted meningococcal (Serogroups A, C, W-135 and Y) glycoconjugate vaccine in healthy infants. Proceedings of the 44th Annual Meeting of IDSA. October 12-15, Toronto (2006)
30. Pace D., and Pollard A.J. Meningococcal A, C, Y, W-135 polysaccharide-protein conjugate vaccines. Arch Dis Child 92 (2007) 905-915